CDC nominee Dr. Erica Schwartz pledged she would not betray scientific evidence during a Senate health committee hearing on July 15, 2026 [1].
The testimony comes amid concerns that political leadership could influence public health guidelines, specifically regarding the promotion of vaccines for children during a severe flu season.
During the hearing before the U.S. Senate Health, Education, Labor and Pensions (HELP) Committee, Senator Maggie Hassan (D-NH) questioned Schwartz on whether she would follow orders to stop promoting the flu vaccine for children [1, 2]. The line of questioning focused on the nominee's ability to lead the agency independently and resist political pressure from the administration [2].
Schwartz said, "I will never betray the science" [1, 3]. She further emphasized the need for openness in government operations to regain the confidence of the public. "We must maintain radical transparency to rebuild public trust," Schwartz said [1].
Lawmakers expressed concern that the CDC's vaccine policies could be compromised by political directives, particularly when facing a deadly flu season for children [1, 4]. The hearing also addressed the nominee's relationship with HHS Secretary Robert F. Kennedy Jr. and whether that dynamic would impact the agency's scientific integrity [1, 5].
Schwartz's commitment to science was a central theme of the proceedings as the committee evaluated her fitness to lead the nation's primary public health agency. The testimony highlighted the ongoing tension between administrative policy goals and established medical protocols [2, 4].
“"I will never betray the science."”
This hearing underscores a critical conflict between political appointees and the scientific autonomy of the CDC. If the nominee's pledge to prioritize science over administrative orders holds, it suggests a firewall between the HHS leadership and the agency's technical guidelines. However, the focus on pediatric flu vaccines indicates that the administration's skepticism toward certain immunization protocols remains a primary point of contention for lawmakers.
